From the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell is in Manhasset, New York, USA.
Department of Cardiovascular and Thoracic Surgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell is in Manhasset, New York, USA.
ASAIO J. 2023 Jun 1;69(6):588-594. doi: 10.1097/MAT.0000000000001894. Epub 2023 Feb 20.
Assessment of frailty is key for evaluation for advanced therapies (ATs). Most programs use a subjective provider assessment (SPA) or "eye-ball" test; however, objective measures exist. The modified five-item Fried Frailty Index (mFFI) is a validated tool to assess frailty. We compared SPA to mFFI testing in patients referred for AT. We also compared levels of macrophage migration inhibitory factor (MIF), an inflammatory biomarker associated with worse outcomes in heart failure, between frail and not frail subjects. Seventy-eight patients referred for evaluation for AT underwent both SPA and mFFI testing. Three cardiac surgeons independently assessed patients for frailty (SPA). SPA significantly underestimated frailty compared with mFFI testing and correlation between SPA and mFFI was not strong (κ = 0.02-0.14). Providers were correct 84% of the time designating a subject as frail, but only 40% of the time designating as not frail. Agreement between all three providers was robust (76%), which was primarily driven by designation as not frail. There was no significant difference in plasma MIF levels between frail and not frail subjects (47.6 ± 25.2 vs . 45.2 ± 18.9 ng/ml; p = 0.6). Clinicians significantly underestimate frailty but are usually correct when designating a patient as frail.
衰弱评估对于先进治疗(AT)的评估至关重要。大多数方案使用主观提供者评估(SPA)或“目测”测试;但是,存在客观措施。改良的五项弗莱德衰弱指数(mFFI)是评估衰弱的有效工具。我们将 SPA 与 AT 患者的 mFFI 测试进行了比较。我们还比较了巨噬细胞移动抑制因子(MIF)水平,MIF 是心力衰竭不良预后相关的炎症生物标志物,在衰弱和非衰弱患者之间。78 名接受 AT 评估的患者接受了 SPA 和 mFFI 测试。三位心脏外科医生独立评估患者的衰弱程度(SPA)。与 mFFI 测试相比,SPA 明显低估了衰弱程度,并且 SPA 和 mFFI 之间的相关性不强(κ=0.02-0.14)。提供者在将受试者指定为衰弱时正确的概率为 84%,但将其指定为非衰弱时的正确率仅为 40%。所有三位提供者之间的一致性很强(76%),这主要是由于将其指定为非衰弱。衰弱和非衰弱患者的血浆 MIF 水平无显著差异(47.6±25.2 与 45.2±18.9ng/ml;p=0.6)。临床医生明显低估了衰弱,但在指定患者衰弱时通常是正确的。